Top Stock Reports for Walmart, Toyota Motor & Boston Scientific
Werte in diesem Artikel
Friday, April 25, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Toyota Motor Corp. (TM) and Boston Scientific Corp. (BSX), as well as a micro-cap stock Autoscope Technologies Corp. (AATC). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Conflicting Claims on U.S./China Trade Sends Pre-Markets in the RedToday's Featured Research ReportsWalmart’s shares have outperformed the Zacks Retail - Supermarkets industry over the past year (+61.1% vs. +58.5%). The company has been benefiting from its diverse business model that spans multiple segments, channels and formats. The company's strong omnichannel strategy has boosted traffic across physical stores and digital platforms. Walmart emphasis on improving delivery services is successful, contributing to steady grocery market share gains. Upsides like these, along with growth in the advertising business, fueled fourth-quarter fiscal 2025 results, wherein the top and bottom lines increased year over year, and e-commerce sales surged. However, Walmart faces a few challenges as it navigates 2025. The shifting tariff environment presents cost pressures, especially with roughly one-third of its U.S. inventory sourced from abroad. Despite challenges from rising tariffs and market uncertainty, the company has reaffirmed its first-quarter fiscal 2026 outlook.(You can read the full research report on Walmart here >>>)Shares of Toyota Motor have outperformed the Zacks Automotive - Foreign industry over the past six months (+5.7% vs. -1.3%). The surge in hybrid adoption is driving the company’s sales, supported by strategic initiatives to accelerate growth and enhance profitability. Toyota Motor is working to restore production to normal levels. While prioritizing hybrids, Toyota remains committed to the BEV market, with plans to introduce solid-state batteries that promise extended range and lower production costs. Investor-friendly moves further bolster optimism. However, significant investments in human capital and expansion initiatives are expected to weigh on operating profits this fiscal year. Elevated R&D expenditures on advanced technologies and alternative fuels support long-term innovation but may constrain near-term margins. Rising debt levels also pose financial challenges. The stock warrants a cautious stance now.(You can read the full research report on Toyota Motor here >>>)Boston Scientific’s shares have outperformed the Zacks Medical - Products industry over the past year (+38.2% vs. +8.1%). The company is seeing strength across target markets despite macroeconomic issues, primarily the tariff tension, and related cost inflation. Strong worldwide demand for its MedSurg and Cardiovascular lines, traction in the U.S. and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers. The Pain and Brain franchisees are gaining solid traction in 2025 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2025 guidance indicating strong organic growth over 2024 builds confidence in the stock. On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds are expected to impact the company’s top line in 2025.(You can read the full research report on Boston Scientific here >>>)Shares of Autoscope Technologies have outperformed the Zacks Technology Services industry over the past year (+47.9% vs. +19.7%). This microcap company with market capitalization of $42.51 million delivers robust profitability through a resilient royalty-based model, generating $13.2 million in royalty income in 2024 with fourth-quarter gross margins rising to 100%. The capital-light structure ensures high operating leverage and stable cash flows. Strategic cost reductions drove a 12% decline in operating expenses, lifting operating income by 33% to $6.2 million. AATC’s ITS solutions align with public infrastructure initiatives, enhancing demand visibility. Continued innovation in AI-enabled platforms like IntelliSight supports its leadership in smart traffic systems. With low capex, 95% gross margins, and minimal supply-chain exposure, the firm maintains agility. A rising regular dividend and a $1.32 special dividend in 2024 reflect financial strength and a 7.74% yield, well above industry norms, underscoring shareholder commitment and long-term value creation.(You can read the full research report on Autoscope Technologies here >>>)Other noteworthy reports we are featuring today include SAP SE (SAP), Chubb Ltd (CB) and NIKE, Inc. (NKE).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadWalmart (WMT) Benefits from Impressive E-Commerce OperationsSurge in Hybrid Adoption Aids Toyota (TM), High Expenses AilNew Buyouts, Endoscopy Growth Aid Boston Scientific (BSX)Featured ReportsBetter Pricing, New Business Growth Drive Chubb Limited (CB)Per the Zacks analyst, Chubb is set to grow on better pricing, new business growth and high renewal rates. Yet exposure to cat loss induces underwriting volatility while rising costs pressurize marginDigital & China Woes Hurt NIKE's (NKE) Sales, Profit MarginsPer the Zacks analyst, NIKE faces challenges from weak sales in its lifestyle segment, declining digital revenues, and issues in Greater China, resulting in soft revenues and compressed profit marginsInfrastructural Investments Aid DTE Energy (DTE) Amid Poor SolvencyPer the Zacks analyst, DTE Energy makes systematic investments to maintain and upgrade the reliability of its infrastructure. Yet its poor financial ratios indicate weak solvency position.Halliburton (HAL) to Benefit from International GrowthThe Zacks analyst likes Halliburton's strong growth at its international business but is worried over the ongoing headwinds from Mexico and tariff uncertainty.Healthy Leasing Aids Federal Realty Amid E-Commerce AdoptionPer the Zacks Analyst, Federal Realty (FRT) is to gain from healthy leasing activity aiding occupancy growth, diverse tenant base and focus on essential retail assets. Yet, e-commerce adoption ails.BEAM's Gene-Therapy Pipeline Holds Promise Amid CompetitionPer the Zacks analyst, BEAM's lead candidate, BEAM-101, a base-editing therapy being developed to treat two rare diseases, holds promise. However, stiff competition in the target market remains a woe.IMAX (IMAX) Banks on Solid Movie Slate, Exclusive PartnershipsPer the Zacks Analyst, IMAX is benefiting from an expanded content portfolio, including local language films and exclusive partnerships.New UpgradesSAP's Cloud Momentum Fuels Strong Top Line GrowthPer the Zacks analyst, SAP is seeing strong momentum from rising cloud demand, fueled by growing adoption of Rise with SAP and Grow with SAP, boosting Cloud ERP Suite sales and cloud revenue growth.Sales Growth & Operational Efficiency Buoys Carvana (CVNA)Retail used car sales growth and cost cuts in reconditioning and inbound transport are expected to boost Carvana's performance further, per Zacks analyst.EverQuote (EVER) Boasts Revenue Growth, Solid Balance SheetPer the Zacks analyst, consumer traffic, quote request volume and innovative advertiser products and services drive EverQuote revenues. Its strong balance sheet enables it to fulfill debt obligations.New DowngradesWerner (WERN) Continues to Grapple With Segmental WeaknessThe Zacks Analyst is worried about the fact that lower revenues across both the Truckload Transportation Services and Logistics segments hurt Werner's top-line results.Seagate (STX) Hit By Macro Challenges & High IndebtednessPer the Zacks analyst, Seagate's performance is plagued by macroeconomic and supply chain woes, rising costs and a massive debt burden. Fierce rivalry from HDD and SSD manufacturers are concerning. MKS Instruments (MKSI) Suffers from Sluggish NAND BusinessPer the Zacks analyst, MKS Instruments suffer from ongoing weakness in specialty industrial markets, NAND, and seasonal slowdowns.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report NIKE, Inc. (NKE): Free Stock Analysis Report Toyota Motor Corporation (TM): Free Stock Analysis Report Walmart Inc. (WMT): Free Stock Analysis Report Chubb Limited (CB): Free Stock Analysis Report SAP SE (SAP): Free Stock Analysis Report Autoscope Technologies Corporation (AATC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Boston Scientific und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Boston Scientific
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Walmart
Analysen zu Walmart
Datum | Rating | Analyst | |
---|---|---|---|
10.04.2025 | Walmart Overweight | JP Morgan Chase & Co. | |
10.04.2025 | Walmart Outperform | RBC Capital Markets | |
10.04.2025 | Walmart Buy | Goldman Sachs Group Inc. | |
10.04.2025 | Walmart Buy | UBS AG | |
04.04.2025 | Walmart Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
10.04.2025 | Walmart Overweight | JP Morgan Chase & Co. | |
10.04.2025 | Walmart Outperform | RBC Capital Markets | |
10.04.2025 | Walmart Buy | Goldman Sachs Group Inc. | |
10.04.2025 | Walmart Buy | UBS AG | |
04.04.2025 | Walmart Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
20.11.2024 | Walmart Halten | DZ BANK | |
17.05.2024 | Walmart Neutral | JP Morgan Chase & Co. | |
16.05.2024 | Walmart Neutral | JP Morgan Chase & Co. | |
21.02.2024 | Walmart Neutral | JP Morgan Chase & Co. | |
20.02.2024 | Walmart Neutral | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
08.05.2019 | Walmart Underperform | Wolfe Research | |
08.11.2018 | Walmart Sell | Morningstar | |
17.11.2017 | Walmart Underperform | RBC Capital Markets | |
10.11.2017 | Walmart Underperform | RBC Capital Markets | |
11.10.2017 | Walmart Underperform | RBC Capital Markets |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Walmart nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen